📰 Dose Escalation Study News
Page 2 - Dose Escalation Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dose Escalation Study. Real-time updates on events, politics, business and more.
November 2, 2023
NEW YORK, November 02, 2023--Schrödinger today announced that new data on SGR-1505, its MALT1 inhibitor, and SGR-2921, its CDC7 inhibitor, will be presented at ASH.
May 25, 2023
FinancialContent fully hosted finance channel
April 18, 2023
/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim...
April 14, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...
April 13, 2023
/PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced that it will present...
April 4, 2023
/PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies long-term...
March 27, 2023
You should read the following discussion and analysis of our financial condition and results of operations together with our audited consolidated financial statements and notes thereto for the... | March 27, 2023
March 14, 2023
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
December 8, 2022
/PRNewswire/ -- Dantari, Inc. ("Dantari"), a clinical-stage biotechnology company developing best-in-class targeted therapeutics for the treatment of cancers...
December 5, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...